ArticleAJPM focus2025
Association of SARS-CoV-2 Serology Test Result and COVID-19 Vaccination in Adults: A Multisite Cohort Study.
Article in AJPM focus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SARS-CoV-2 humoral immunity is associated with elevated hemoglobin A1c.Laboratory medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although the utility of SARS-CoV-2 serology testing is limited, individuals may have used serology test results to inform COVID-19 vaccination decisions during the pandemic. Serology test results may have changed individuals' perceived susceptibility to SARS-CoV2 infection, leading to risk compensation behavior. Understanding how serology results as a measure of perceived susceptibility influence COVID-19 vaccination decisions could inform future interventions to increase adult vaccine acceptance. This study examined the association between SARS-CoV-2 serology (antibody) test results and COVID-19 vaccination uptake. Methods: This retrospective cohort study included adults who received ≥1 serology test between January 1, 2021, and February 28, 2023. The date of the first serology test represented Day 0, and vaccination uptake was followed for 30 days. Individuals could have multiple serology tests, and person-time follow-up was enumerated across tests. The main exposure was the SARS-CoV-2 serology test result. Receipt of COVID-19 vaccination (BNT162b2 or mRNA-1273) was analyzed using Cox proportional hazards regression, controlling for age, sex, race/ethnicity, tobacco use, and comorbidities. Results: Within a cohort of 28,610 adults, there were 28,820 serology test results. Approximately 38% ( Conclusions: SARS-CoV-2 serology results appear to influence vaccination behavior. Future interventions could target perceived illness susceptibility to increase vaccine acceptance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.